Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in <i>ALK</i>-positive NSCLC, Published online: 16 November 2017; doi:10.1038/bjc.2017.395
from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2zJJ7Dj
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,